CellsBin

CellsBin has raised a Series A round led by 108 BioCapital to advance its rare-cell intelligence platform. The company develops technology for detecting and analyzing rare cells, an area of growing interest in diagnostics and life sciences research. The funding is expected to support further development of its platform as investor attention on biology and precision-medicine tools continues to build.